CytomX Therapeutics (CTMX) EPS (Weighted Average and Diluted) (2019 - 2026)
CytomX Therapeutics (CTMX) reported EPS (Weighted Average and Diluted) of -$0.1 for Q1 2026, down 137.04% on a YoY basis from $0.27 in Q1 2025, and up 54.55% quarter-over-quarter from -$0.22 in Q4 2025.
CytomX Therapeutics (CTMX) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
CytomX Therapeutics has reported EPS (Weighted Average and Diluted) for 8 years, with the latest figure at -$0.1 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 137.04% year-over-year to -$0.1; the trailing twelve-month figure through Mar 2026 stood at -$0.41 (down 183.67% YoY), and the FY2025 full-year result was -$0.15, down 139.47% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.1, up from -$0.22 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.27 in Q1 2025, with the low at -$0.49 in Q1 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.08 across 5 years, with a median of -$0.06 in 2023.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 2200.0% in 2024 against a maximum downside of 300.0% in 2024.
- CytomX Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.13 in 2022, then jumped by 107.69% to $0.01 in 2023, then jumped by 2200.0% to $0.23 in 2024, then sank by 195.65% to -$0.22 in 2025, then surged by 54.55% to -$0.1 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.1 (Q1 2026), -$0.22 (Q4 2025), and -$0.09 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | CytomX Therapeutics | 520.30 Mn | 173.59 Mn | - | -0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.10 |
| Dec 31, 2025 | -0.22 |
| Sep 30, 2025 | -0.09 |
| Mar 31, 2025 | 0.27 |
| Dec 31, 2024 | 0.23 |
| Sep 30, 2024 | 0.07 |
| Jun 30, 2024 | -0.08 |
| Mar 31, 2024 | 0.17 |
| Dec 31, 2023 | 0.01 |
| Sep 30, 2023 | 0.04 |
| Jun 30, 2023 | -0.02 |
| Mar 31, 2023 | -0.05 |
| Dec 31, 2022 | -0.13 |
| Sep 30, 2022 | -0.44 |
| Jun 30, 2022 | -0.45 |
| Mar 31, 2022 | -0.49 |
| Dec 31, 2021 | -0.53 |
| Sep 30, 2021 | -0.48 |
| Jun 30, 2021 | -0.41 |
| Mar 31, 2021 | -0.38 |